{"success":true,"data":{"pressRelease":{"id":"81402","rtpr_id":"nGNXS6sn6","ticker":"EMBC","exchange":"NASDAQ","all_tickers":["EMBC"],"title":"Embecta Corp. (EMBC) Faces Securities Class Action Over Alleged Concealed Material Risks to Pen Needle Revenue – HBSS","author":"Globe Newswire","published_at":"2026-07-06T21:20:39.099Z","article_body":"SAN FRANCISCO, July 06, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (NASDAQ: EMBC)\nfaces a securities class action lawsuit, which seeks to represent investors\nwho purchased or acquired Embecta common stock between November 25, 2025 and\nMay 4, 2026. The lawsuit follows the company’s disastrous Q2 2026 earnings\nreport, apparently at odds with prior narrative, which triggered a massive\nselloff in the stock and analysts’ questions.\n\nThese developments have prompted national shareholder rights firm Hagens\nBerman to open an investigation into claims that Embecta violated the federal\nsecurities laws.\n\nThe firm encourages Embecta investors who suffered substantial losses to\nsubmit your losses now\n(https://www.globenewswire.com/Tracker?data=S4BhBjq3EIR-T74hy16Bv7npo4nQGTfihZGOrm8lujsGJai9ud7_34qGrbV3On4-JSut59LL1WC3MmizzUWwisjxHTfqhUZZ0TISnoTOf0l0fCilloX2RP6Dtq9FSkOg).\n\nClass Period: Nov. 25, 2025 – May 4, 2026\nLead Plaintiff Deadline: Aug. 17, 2026\nVisit: www.hbsslaw.com/investor-fraud/embc \nContact the Firm Now: EMBC@hbsslaw.com | 844-916-0895\n\nEmbecta Corp. (EMBC) Securities Class Action:\n\nEmbecta is a global medical device company whose core business product is pen\nneedles – sterile, single-use, medical devices, designed to be used in\nconjunction with pen injectors that inject insulin or other diabetes\nmedications. In the past, pen needle revenues have comprised over 70% of the\ncompany’s total revenues.\n\nThe litigation’s primary focus is on the propriety of Embecta’s Class\nPeriod repeated assurances that “insulin pens have been stable […] showing\nthe underlying resilience and the durability of that portfolio[]” and “our\npen needle business is incredibly resolute.” This narrative formed the basis\nfor the company’s February 5, 2026 guidance reiterating 2026 adjusted EPS of\n$2.80 - $3.00. The company also touted maintenance of its dividend within its\ncapital allocation plans as a return of capital to shareholders.\n\nThe complaint alleges the company’s assurances and guidance were misleading\nwhen given because Embecta knew or recklessly disregarded that weaknesses in\nthe pen needle market was likely to significantly disrupt the company’s\nannual guidance and Q2 results.\n\nOn May 5, 2026, investors’ expectations vanished. That day, Embecta reported\nQ2 2026 adjusted EPS of $0.27, a staggering sequential and year-over-year\ndecline of about 61%. In contrast to the company’s assurances of stability,\nresilience, and durability, Embecta’s pen needles revenues also suffered\nmassive sequential and year-over-year declines. Of additional concern, Embecta\nslashed its 2026 adjusted EPS guidance to $1.55 - $1.75, or down roughly 43%\nat the mid-point, and reduced its dividend by 93% to just $0.01.\n\nIn response, the market sent the price of Embecta shares tumbling, with one\nprominent analyst who downgraded the company highlighting Embecta\nmanagement’s “need to rebuild investor credibility on commercial execution\nand the profitability outlook.”\n\n“Our investigation is focused the extent to which and when Embecta and its\nmanagement knew about pen needle and U.S. business revenue headwinds, and\nwhether they were sufficiently transparent about those risks,” said Reed\nKathrein\n(https://www.globenewswire.com/Tracker?data=2tWuyms02ZHRC5mkYyV-8mxOZpXN7UUvhirVdfL3Yf3bIU8qHOOUxyg2v6yqBTemsdo7JoI4GEbCtjmo0aDQvTi2NL-aFNIJxLQ2GgUvgKULFMflcjWnQWMtPxOMSRZR),\nthe Hagens Berman partner leading the firm’s investigation.\n\nIf you invested in Embecta and have substantial losses, or have knowledge that\nwill assist the firm’s investigation, submit your losses now\n(https://www.globenewswire.com/Tracker?data=S4BhBjq3EIR-T74hy16Bv7npo4nQGTfihZGOrm8lujuph7CvJbsBPn-pvERY1pujotHugHfthxvikQM6EOBwYcrMfkXGjT6Tp7R-kXVO1UCJjUaMad756ELVS9uGqe-z).\n\nIf you’d like more information and answers to other frequently asked\nquestions about the Embecta case and the firm’s investigation, read more\n(https://www.globenewswire.com/Tracker?data=epDaAP65YhoudMeXYCVKSFmH9L_-GJSwMMwoMxosTwbndiGYGu43nlD97gfNuO9YTYIS-TglG1xamatY7tR2qQj4XeEYhzbLTRUU2Mk4OEkQhp5z2VkFnO0hlk9ZMUV5XdjYRFWrRrdPIpwSm85vmg==).\n\nWhistleblowers: Persons with non-public information regarding Embecta should\nconsider their options to help in the investigation or take advantage of the\nSEC Whistleblower program. Under the new program, whistleblowers who provide\noriginal information may receive rewards totaling up to 30 percent of any\nsuccessful recovery made by the SEC. For more information, call Reed Kathrein\nat 844-916-0895 or email EMBC@hbsslaw.com.\n\nAbout Hagens Berman\n(https://www.globenewswire.com/Tracker?data=ntegAavUxxWSLpdHtd84Yq-3MGQBmpUvyBGGBCfjeiziNHiJHq6UrVR_NybN9yTJJhmMDQo3tqio_Z8ViAOmbDAHzuayyDjSPxuRI_HxIww=)\nHagens Berman is a global plaintiffs’ rights complex litigation firm\nfocusing on corporate accountability. The firm is home to a robust practice\nand represents investors as well as whistleblowers, workers, consumers and\nothers in cases achieving real results for those harmed by corporate\nnegligence and other wrongdoings. Hagens Berman’s team has secured more than\n$2.9 billion in this area of law. More about the firm and its successes can be\nfound at hbsslaw.com\n(https://www.globenewswire.com/Tracker?data=j6VPIyf1S8nkDzko7uzC9_8mdOdB2gMoGkDxDm8j9ILp9IBHfLF9gnmtO15YYSInA7tFNYCXjrvBoGs4gvM_zw==).\nFollow the firm for updates and news at @ClassActionLaw. \n\nAttorney Advertising. Prior results do not guarantee a similar outcome in any\nfuture case.\n\nContact: \nReed Kathrein, 844-916-0895\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2c81cd72-0ffb-43c9-9d0f-b622c3e44e43)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXS6sn6","title":"Embecta Corp. (EMBC) Faces Securities Class Action Over Alleged Concealed Material Risks to Pen Needle Revenue – HBSS","author":"Globe Newswire","ticker":"EMBC","created":"2026-07-06T21:20:39.099Z","tickers":["EMBC"],"exchange":"NASDAQ","article_body":"SAN FRANCISCO, July 06, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (NASDAQ: EMBC)\nfaces a securities class action lawsuit, which seeks to represent investors\nwho purchased or acquired Embecta common stock between November 25, 2025 and\nMay 4, 2026. The lawsuit follows the company’s disastrous Q2 2026 earnings\nreport, apparently at odds with prior narrative, which triggered a massive\nselloff in the stock and analysts’ questions.\n\nThese developments have prompted national shareholder rights firm Hagens\nBerman to open an investigation into claims that Embecta violated the federal\nsecurities laws.\n\nThe firm encourages Embecta investors who suffered substantial losses to\nsubmit your losses now\n(https://www.globenewswire.com/Tracker?data=S4BhBjq3EIR-T74hy16Bv7npo4nQGTfihZGOrm8lujsGJai9ud7_34qGrbV3On4-JSut59LL1WC3MmizzUWwisjxHTfqhUZZ0TISnoTOf0l0fCilloX2RP6Dtq9FSkOg).\n\nClass Period: Nov. 25, 2025 – May 4, 2026\nLead Plaintiff Deadline: Aug. 17, 2026\nVisit: www.hbsslaw.com/investor-fraud/embc \nContact the Firm Now: EMBC@hbsslaw.com | 844-916-0895\n\nEmbecta Corp. (EMBC) Securities Class Action:\n\nEmbecta is a global medical device company whose core business product is pen\nneedles – sterile, single-use, medical devices, designed to be used in\nconjunction with pen injectors that inject insulin or other diabetes\nmedications. In the past, pen needle revenues have comprised over 70% of the\ncompany’s total revenues.\n\nThe litigation’s primary focus is on the propriety of Embecta’s Class\nPeriod repeated assurances that “insulin pens have been stable […] showing\nthe underlying resilience and the durability of that portfolio[]” and “our\npen needle business is incredibly resolute.” This narrative formed the basis\nfor the company’s February 5, 2026 guidance reiterating 2026 adjusted EPS of\n$2.80 - $3.00. The company also touted maintenance of its dividend within its\ncapital allocation plans as a return of capital to shareholders.\n\nThe complaint alleges the company’s assurances and guidance were misleading\nwhen given because Embecta knew or recklessly disregarded that weaknesses in\nthe pen needle market was likely to significantly disrupt the company’s\nannual guidance and Q2 results.\n\nOn May 5, 2026, investors’ expectations vanished. That day, Embecta reported\nQ2 2026 adjusted EPS of $0.27, a staggering sequential and year-over-year\ndecline of about 61%. In contrast to the company’s assurances of stability,\nresilience, and durability, Embecta’s pen needles revenues also suffered\nmassive sequential and year-over-year declines. Of additional concern, Embecta\nslashed its 2026 adjusted EPS guidance to $1.55 - $1.75, or down roughly 43%\nat the mid-point, and reduced its dividend by 93% to just $0.01.\n\nIn response, the market sent the price of Embecta shares tumbling, with one\nprominent analyst who downgraded the company highlighting Embecta\nmanagement’s “need to rebuild investor credibility on commercial execution\nand the profitability outlook.”\n\n“Our investigation is focused the extent to which and when Embecta and its\nmanagement knew about pen needle and U.S. business revenue headwinds, and\nwhether they were sufficiently transparent about those risks,” said Reed\nKathrein\n(https://www.globenewswire.com/Tracker?data=2tWuyms02ZHRC5mkYyV-8mxOZpXN7UUvhirVdfL3Yf3bIU8qHOOUxyg2v6yqBTemsdo7JoI4GEbCtjmo0aDQvTi2NL-aFNIJxLQ2GgUvgKULFMflcjWnQWMtPxOMSRZR),\nthe Hagens Berman partner leading the firm’s investigation.\n\nIf you invested in Embecta and have substantial losses, or have knowledge that\nwill assist the firm’s investigation, submit your losses now\n(https://www.globenewswire.com/Tracker?data=S4BhBjq3EIR-T74hy16Bv7npo4nQGTfihZGOrm8lujuph7CvJbsBPn-pvERY1pujotHugHfthxvikQM6EOBwYcrMfkXGjT6Tp7R-kXVO1UCJjUaMad756ELVS9uGqe-z).\n\nIf you’d like more information and answers to other frequently asked\nquestions about the Embecta case and the firm’s investigation, read more\n(https://www.globenewswire.com/Tracker?data=epDaAP65YhoudMeXYCVKSFmH9L_-GJSwMMwoMxosTwbndiGYGu43nlD97gfNuO9YTYIS-TglG1xamatY7tR2qQj4XeEYhzbLTRUU2Mk4OEkQhp5z2VkFnO0hlk9ZMUV5XdjYRFWrRrdPIpwSm85vmg==).\n\nWhistleblowers: Persons with non-public information regarding Embecta should\nconsider their options to help in the investigation or take advantage of the\nSEC Whistleblower program. Under the new program, whistleblowers who provide\noriginal information may receive rewards totaling up to 30 percent of any\nsuccessful recovery made by the SEC. For more information, call Reed Kathrein\nat 844-916-0895 or email EMBC@hbsslaw.com.\n\nAbout Hagens Berman\n(https://www.globenewswire.com/Tracker?data=ntegAavUxxWSLpdHtd84Yq-3MGQBmpUvyBGGBCfjeiziNHiJHq6UrVR_NybN9yTJJhmMDQo3tqio_Z8ViAOmbDAHzuayyDjSPxuRI_HxIww=)\nHagens Berman is a global plaintiffs’ rights complex litigation firm\nfocusing on corporate accountability. The firm is home to a robust practice\nand represents investors as well as whistleblowers, workers, consumers and\nothers in cases achieving real results for those harmed by corporate\nnegligence and other wrongdoings. Hagens Berman’s team has secured more than\n$2.9 billion in this area of law. More about the firm and its successes can be\nfound at hbsslaw.com\n(https://www.globenewswire.com/Tracker?data=j6VPIyf1S8nkDzko7uzC9_8mdOdB2gMoGkDxDm8j9ILp9IBHfLF9gnmtO15YYSInA7tFNYCXjrvBoGs4gvM_zw==).\nFollow the firm for updates and news at @ClassActionLaw. \n\nAttorney Advertising. Prior results do not guarantee a similar outcome in any\nfuture case.\n\nContact: \nReed Kathrein, 844-916-0895\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2c81cd72-0ffb-43c9-9d0f-b622c3e44e43)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-06T21:20:39.143653015Z","server_sent_at_ms":1783372839143},"received_at":"2026-07-06T21:20:39.209Z","source_url":null},"analysis":{"id":"70513","press_release_id":"81402","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Hagens Berman announced an investigation into Embecta regarding a securities class action lawsuit focused on alleged misleading statements about pen needle revenue stability.\n\nThe lawsuit follows a significant Q2 2026 miss, where adjusted EPS fell 61% to $0.27 and the company slashed its full-year guidance range by roughly 43% at the midpoint.\n\nInvestors who purchased shares between November 25, 2025, and May 4, 2026, are being encouraged to contact the firm before the lead plaintiff deadline of August 17, 2026.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"customDimensions":{"reduced_dividend":"$0.01","q2_eps_decline_pct":"61%","q2_2026_adjusted_eps":"$0.27","new_guidance_2026_eps":"$1.55 - $1.75","dividend_reduction_pct":"93%","prior_guidance_2026_eps":"$2.80 - $3.00","guidance_reduction_midpoint_pct":"43%"}},"quotedText":"Our investigation is focused the extent to which and when Embecta and its management knew about pen needle and U.S. business revenue headwinds, and whether they were sufficiently transparent about those risks,","namedEntities":{"people":[{"name":"Reed Kathrein","role":"Partner, Hagens Berman"}],"products":["pen needles"],"companies":[{"name":"Embecta Corp.","ticker":"EMBC","relationship":"target"},{"name":"Hagens Berman","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$2.80 - $3.00","context":"2026 adjusted EPS guidance (prior)"},{"amount":"$0.27","context":"Q2 2026 adjusted EPS (reported)"},{"amount":"$1.55 - $1.75","context":"2026 adjusted EPS guidance (reduced)"},{"amount":"$0.01","context":"dividend (reduced)"},{"amount":"$2.9 billion","context":"recoveries secured by Hagens Berman"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Hagens Berman. No new disclosure from the issuer; no certified class, no settlement. Boilerplate investigation announcement and lead-plaintiff deadline reminder."},"tickerRelevance":{"others":[],"primary":"EMBC"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Hagens Berman announced an investigation into Embecta regarding a securities class action lawsuit focused on alleged misleading statements about pen needle revenue stability.\n\nThe lawsuit follows a significant Q2 2026 miss, where adjusted EPS fell 61% to $0.27 and the company slashed its full-year guidance range by roughly 43% at the midpoint.\n\nInvestors who purchased shares between November 25, 2025, and May 4, 2026, are being encouraged to contact the firm before the lead plaintiff deadline of August 17, 2026.","key_figures":{"customDimensions":{"reduced_dividend":"$0.01","q2_eps_decline_pct":"61%","q2_2026_adjusted_eps":"$0.27","new_guidance_2026_eps":"$1.55 - $1.75","dividend_reduction_pct":"93%","prior_guidance_2026_eps":"$2.80 - $3.00","guidance_reduction_midpoint_pct":"43%"}},"named_entities":{"people":[{"name":"Reed Kathrein","role":"Partner, Hagens Berman"}],"products":["pen needles"],"companies":[{"name":"Embecta Corp.","ticker":"EMBC","relationship":"target"},{"name":"Hagens Berman","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$2.80 - $3.00","context":"2026 adjusted EPS guidance (prior)"},{"amount":"$0.27","context":"Q2 2026 adjusted EPS (reported)"},{"amount":"$1.55 - $1.75","context":"2026 adjusted EPS guidance (reduced)"},{"amount":"$0.01","context":"dividend (reduced)"},{"amount":"$2.9 billion","context":"recoveries secured by Hagens Berman"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-06T21:22:32.236Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":113016,"modelName":"george-droid-qwen-72b"}}